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Anti-ganglioside antibodies are removed from
circulation in mice by neuronal endocytosis
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In axonal forms of Guillain-Barre´ syndrome, anti-ganglioside antibodies bind gangliosides on nerve surfaces, thereby causing injury through
complement activation and immune cell recruitment. Why some nerve regions are more vulnerable than others is unknown. One reason
may be that neuronal membranes with high endocytic activity, including nerve terminals involved in neurotransmitter recycling, are able to
endocytose anti-ganglioside antibodies from the cell surface so rapidly that antibody-mediated injury is attenuated. Herein we investigated
whether endocytic clearance of anti-ganglioside antibodies by nerve terminals might also be of sufﬁcient magnitude to deplete circulating
antibody levels. Remarkably, systemically delivered anti-ganglioside antibody in mice was so avidly cleared from the circulation by endo-
cytosis at ganglioside-expressing plasma membranes that it was rapidly rendered undetectable in serum. A major component of the clearance
occurred at motor nerve terminals of neuromuscular junctions, from where anti-ganglioside antibody was retrogradely transported to the
motor neuron cell body in the spinal cord, recycled to the plasma membrane, and secreted into the surrounding spinal cord. Uptake at the
neuromuscular junction represents a major unexpected pathway by which pathogenic anti-ganglioside antibodies, and potentially other
ganglioside binding proteins, are cleared from the systemic circulation and also covertly delivered to the central nervous system.
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Introduction
The Guillain-Barre´ syndromes are autoimmune neuropathies in
which immune factors acutely injure nerves (van den Berg et
al., 2014). In axonal forms of Guillain-Barre´ syndrome, neuro-
toxic anti-ganglioside antibodies (AGAbs) bind to gangliosides
on exposed axolemmal membranes where they ﬁx complement
(Plomp and Willison, 2009). Gangliosides are ubiquitous, yet
very highly enriched in neurons and their projecting axons,
including the presynaptic neuromuscular junction (NMJ),
residing in the outer leaﬂet of the plasma membrane facing
the extracellular milieu of the synaptic cleft (Schengrund,
2015). The NMJ is a major site of AGAb binding but is rela-
tively resistant to complement-mediated injury due to rapid in-
ternalization of antibody by endocytosis, compared with the
endocytically inactive node of Ranvier, which is highly vulner-
able to injury (Fewou et al., 2012). Conversely, clostridial
neurotoxins require endocytic uptake to mediate their neuro-
toxicity (Rummel, 2013). Similarly, endocytic uptake is a major
internalization pathway for growth factors, antibodies and
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viruses (Ritchie et al., 1986; Fewou et al., 2014; Schengrund,
2015). Herein we analysed the effect of neuronal endocytic
uptake on clearance of AGAb from the systemic circulation.
Materials and methods
Mice
Male and female wild-type, GalNAcT/ and GalNAcT/-
Tg(neuronal) were used at 6–8 weeks (for in vivo) or 8–12
weeks of age (for ex vivo). Mice of different genotypes were
age-matched and where possible, littermate controls were used.
For ex vivo studies, mice were cross-bred with B6.Cg-
Tg(Thy1-CFP/S100B-GFP) transgenic mice, expressing cyan
ﬂuorescent protein (CFP) and green ﬂuorescent protein (GFP)
in their axons and Schwann cells, respectively (Feng et al.,
2000; Zuo et al., 2004). All procedures were conducted in
accordance with the United Kingdom Animals (Scientiﬁc
Procedures) Act of 1986.
Anti-ganglioside antibodies and
normal human serum
All AGAbs used were generated previously by immunization of
ganglioside-deﬁcient mice with ganglioside liposomes or gan-
glioside-mimicking Campylobacter jejuni lipo-oligosaccharide
as described previously (Bowes et al., 2002; Boffey et al.,
2005). The origin and properties of these antibodies have pre-
viously been reported (Greenshields et al., 2009). Normal
human serum as a source of human complement was taken
from a single donor and stored in aliquots at80 C.
Ex vivo internalization studies
Triangularis sterni muscle was dissected and mounted in
Ringer’s solution as described previously (McGonigal et al.,
2010). Muscles were labelled with AGAb (100 mg/ml) plus 2
mg/ml alpha-bungarotoxin (BTx, Alexa Fluor 488 or 647)
(Molecular Probes) for 30min at 4 C. Temperature-dependent
internalization studies were performed as previously described
(Fewou et al., 2012), using wild-type, GalNAcT/ and
GalNAcT/-Tg(neuronal) triangularis sterni with secondary
antibodies applied overnight.
For stimulation-dependent internalization studies, following
initial AGAb labelling and washing steps, intercostal nerves
were stimulated with a Grass SD9 square pulse stimulator
(Natus Medical Inc) using platinum electrodes (5 s at 10Hz,
30 V with a pulse duration of 0.3ms) before ﬁxation for
immunohistology. Botulinum toxin A (BoNT/A) was added
in one experimental group to demonstrate that blocking syn-
aptic vesicle docking prevents the uptake of AGAb in response
to stimulation. Details can be found in the Supplementary
material.
To assess whether rapid AGAb uptake induced by synaptic
activity resulted in protection of the nerve terminal from com-
plement-mediated injury, triangularis sterni muscles were trea-
ted with 40% normal human serum in Ringer’s solution for
30min at 37 C. Membrane attack complex (MAC) was iden-
tiﬁed as previously described (Halstead et al., 2008).
In vivo anti-ganglioside antibody
clearance studies
Following a baseline blood sample taken 1 day prior, mice
were administered 250mg of AGAb intraperitoneally. Further
blood samples were taken by tail vein venesection on Days 1,
3, 6 and upon sacriﬁce. Cervical cord (C4-C6) were removed
and post-ﬁxed in 4% paraformaldehyde overnight at 4 C,
then in 30% sucrose overnight at 4 C. Details of staining
procedures are provided in the Supplementary material.
Full details of exercise studies are provided in the
Supplementary material
Image acquisition and quantitation
Images for analysis of ﬂuorescent intensity were captured using
an LSM 5 Pascal confocal microscope and image analysis was
performed using ImageJ software as previously described
(Greenshields et al., 2009). Illustrative images were captured
using a Zeiss AxioImager Z1 microscope with ApoTome at-
tachment. For antibody intensity measurements in triangularis
sterni preparations, 15 images were taken per triangularis
sterni. For spinal cord, nine images were captured per mouse.
Ganglioside liposome immunization
Liposomes were prepared as per previously described (Bowes
et al., 2002), stored at 4 C until used and kept for up to 5
days. Immunizations were carried out using the protocol
described in Fig. 3.
Enzyme-linked immunosorbent
assays
To test for anti-ganglioside antibody reactivity in serum, ELISAs
were performed as per previously described protocol (Greenshields
et al., 2009). Sera from mice were applied at 1/100 dilution.
Glycoarray
Using combinatorial glycoarray (Rinaldi et al., 2009), sera and
monoclonal antibodies were tested against single lipids and
lipids complexes using a procedure that was modiﬁed for use
with ﬂuorescence readout, as previously described. Full details
of the protocol are provided in the Supplementary material.
ELISpots
To quantitatively determine ganglioside antigen-speciﬁc antibody
responses in mice that were immunized with ganglioside lipo-
somes, ELISpots were performed using splenocytes. The detailed
ELISpot protocol is provided in the Supplementary material.
Experimental design
Mice were assigned to each experiment depending on the avail-
ability of age-matched mice across genotypes. Mice were coded
and assigned to genotype groups after analysis. Sample size es-
timation was chosen using Gpower software (v 3.1.9.2), with
an -error of 0.05 and a power of 0.8. For in vivo clearance
studies, based on preliminary data, an effect size of 2.5 was
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chosen, while for antibody intensity measurements (where indi-
vidual NMJs or NeuN positive cells were ranked) an effect size
of 0.4 was chosen. Sample sizes also corresponded with previ-
ous similar studies (Greenshields et al., 2009).
Statistical analysis
All statistics were performed using GraphPad Prism 6, assum-
ing a signiﬁcance level of 0.05. Outliers of antibody intensity
measurements were removed via ROUT analysis (Q = 1%).
Non-parametric data were analysed by either Mann-Whitney
or Kruskal-Wallis test (with Dunn’s multiple comparison test)
and displayed as Tukey’s box and whisker plots showing the
spread of all NMJs or NeuN positive cells analysed per con-
dition. Details of box and whisker plots are provided in the
Supplementary material. Parametric data were compared by
either Student’s t -test or one- or two-way ANOVA (see
ﬁgure legends). Contingent data were compared by Fisher’s
exact test or Chi-squared test.
Results
When wild-type mice are passively immunized with mono-
clonal anti-GD1b IgG AGAb (250 mg intraperitoneally), we
observed that the AGAb were greatly reduced in the circu-
lation only 24h after injection, representing much faster
clearance than previously reported for antibodies of the
same isotype (Zuckier et al., 1989) (Fig. 1A). To demon-
strate clearance was antigen-dependent, AGAbs were also
passively transferred to GalNAcT/mice, which synthesize
no complex gangliosides and are thus completely devoid of
AGAb targets (Takamiya et al., 1996). In GalNAcT/ mice,
anti-GD1b AGAb levels were still highly elevated after 1
week. As ganglioside expression is widespread throughout
the body, albeit enriched in the nervous system, many cell
types are potentially responsible for antigen-speciﬁc AGAb
clearance. To identify the speciﬁc contribution of neuronal
AGAb uptake on systemic depletion of AGAb, we passively
immunized mice in which GalNAcT enzyme activity, and
thus complex ganglioside expression, is limited to neurons
[GalNAcT/-Tg(neuronal)] (Yao et al., 2014). In these
mice, circulating anti-GD1b AGAb decayed prematurely to
undetectable levels by Day 6. Thus, the contribution of neur-
onal clearance alone, compared to systemic AGAb depletion,
is substantial.
To investigate how endocytic uptake might affect clear-
ance of AGAbs with different avidities for membrane gan-
gliosides, we passively immunized mice with two different
anti-GM1 IgG mAbs, DG1 and DG2 previously reported in
detail (Greenshields et al., 2009). Importantly, DG1 binds
GM1 strongly in ELISA-based immunoassays but is unable
to bind GM1 in intact plasma membranes due to steric
hindrance from laterally-interacting gangliosides (a prin-
ciple well recognized among AGAbs) (Greenshields et al.,
2009; Rinaldi et al., 2009). In contrast, DG2 binds GM1
strongly both in immunoassays and in plasma membranes.
As predicted, the non-tissue binding AGAb DG1 remained
highly elevated in the serum of all three genotypes through-
out the experimental time course. In contrast, AGAb DG2
is never detectable in the circulation of wild-type mice, re-
mains highly elevated after 7 days in the GM1-deﬁcient
GalNAcT/ mice and at intermediate levels in
GalNAcT/-Tg(neuronal) mice (Fig. 1A). In conclusion,
AGAb clearance is an antigen-speciﬁc process that requires
plasma membrane ganglioside binding to occur.
Furthermore, a high proportion of AGAb is cleared solely
by binding to neuronal gangliosides.
From prior work we expect the NMJ to be the major
neuronal uptake pathway for AGAbs (Plomp and Willison,
2009). In ex vivo triangularis sterni neuromuscular prepar-
ations, anti-GD1b mAb antibody bound on the surface of
wild-type (Fig. 1B) and GalNAcT/-Tg(neuronal) NMJ
plasma membranes (Fig. 1C) and was subsequently inter-
nalized within 1 h, but in contrast failed to bind (or
be internalized) at the GD1b-deﬁcient GalNAcT/ NMJ
(Fig. 1D). Internalization was assessed by permeabilizing
the plasma membrane with TritonTM X-100, thereby allow-
ing secondary antibody access and thus visualization of
intracellular AGAb. As ganglioside binding toxins, includ-
ing tetanus and cholera toxin, are known to be retrogradely
transported to the spinal cord (Stoeckel et al., 1977), we
then examined the ventral horns in the spinal cord of pas-
sively immunized mice at 24 h post-immunization and
observed signiﬁcant AGAb deposits in anterior horn cells
of GalNAcT/-Tg(neuronal) mice and minor deposits in
wild-type mice, whereas in GalNAcT/ mice no deposits
were observed, as expected (Fig. 1E). By 5 days the AGAb
had trafﬁcked out of anterior horn cells into adjacent
neuropil of the spinal cord (Fig. 1F). As wild-type mice
have the potential to clear AGAbs through all ganglio-
side-expressing plasma membranes, these data suggest
that widespread and rapid clearance of AGAb in wild-
type mice takes place throughout the body where the
target is expressed, and thus the amount available for neur-
onal clearance is relatively lower than in GalNAcT/-
Tg(neuronal) mice. Conversely, since neurons are the only
possible ganglioside-mediated clearance route available in
GalNAcT/-Tg(neuronal) mice, the AGAb becomes
highly concentrated in the motor neuron and its trafﬁcking
pathways. Within the spinal cord 5 days post-immuniza-
tion, trafﬁcked AGAb was not associated with speciﬁc
cell types, including neuronal (cell body or dendrite) or
glial membranes (Fig. 1G). Other peripherally exposed syn-
apses that would be expected to express gangliosides in
GalNAcT/-Tg(neuronal) mice, and thus endocytose anti-
body include those in post-ganglionic autonomic neurons;
these were not examined. Although peripheral sensory
nerve terminals were not directly examined, surface de-
posits of antibody were observed on some dorsal root
ganglia cell bodies (Fig. 1H) in the absence of any visible
internalized antibody over this time period. No antibody
deposits were observed in central sensory connections in
the dorsal horn of the spinal cord, rather the AGAb is
highly concentrated in the ventral horn cell bodies and
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Figure 1 Anti-ganglioside antibody is internalized at the motor nerve terminal and trafficked to the spinal cord. (A) Serum
levels of monoclonal antibodies over 7 days following i.p. injection of 250 mg. Wild-type mice (n = 9), which have the highest expression of
ganglioside antigen clear antibody most rapidly while GalNAcT/ mice (n = 8) retain circulating anti-ganglioside antibody over 7 days.
GalNAcT/-Tg(neuronal) mice (n = 9) show intermediate rate of clearance. Antibody that cannot bind target ganglioside in live tissue but is
known to bind by ELISA is not cleared in any genotype. Significance versus wild-type, #Significance versus GalNAcT/ P5 0.05, P5 0.001,
P5 0.0001 versus wild-type. ##P5 0.01 versus GalNAcT/, two-way ANOVA with Tukey’s multiple comparison test. (B) Wild-type motor
endplates from triangularis sterni muscle (n = 3 animals) were labelled at 0min with anti-GD1b antibody, and upon incubation at 37 C for 60min,
labelling is reduced (middle column). Permeabilization of the membrane with TritonTM X-100 and reprobing with secondary antibody reveals
presence of antibody within the motor nerve terminal. (C) Illustrative images show NMJs from GalNAcT/-Tg(neuronal) mice (n = 3 animals)
were labelled at 0min with anti-GD1b antibody, but upon incubation at 37 C, labelling is no longer present. Permeabilization of the membrane
with TritonTM X-100 and reprobing with secondary antibody reveals presence of antibody within the motor nerve terminal. Graphs show
quantification of antibody binding in GalNAcT/-Tg(neuronal) mice, where surface labelling at 60min timepoint is significantly reduced compared
to 0min before permeabilization, but statistically similar following permeabilization and reprobing with secondary antibody. P5 0.0001 versus
0min, Kruskal-Wallis with Dunn’s multiple comparisons test. Controls are secondary antibody only. (D) In GalNAcT/ mice, motor endplates
(n = 3 animals) showed no anti-GD1b antibody binding at 0min, nor following 60min incubation at 37 C. Permeabilization of the membrane with
TritonTM X-100 shows no antibody presence in the nerve terminal. (E) One day following a 1mg injection of anti-GD1b Ab (n = 3 per group),
GalNAcT/-Tg(neuronal) mice showed presence of anti-GD1b Ab in the ventral horn neurons, which was significantly higher (P5 0.0001)
than both wild-type and GalNAcT/ mice by positive/negative cell counts (chi-squared test followed by multiple Fisher’s exact tests) and intensity
of AGAb over NeuN staining (Kruskal-Wallis with Dunn’s multiple comparison test). (F) Cords taken 5 days after MOG1 injection appeared to
only show antibody in the neuropil surrounding the neuron body. (G) Antibody localization in GalNAcT/-Tg(neuronal) mice spinal cord after
5 days. Antibody did not appear to be localized to axons (NF-H), myelin (MBP) or astrocytes (GFAP) when translocated from the spinal neuron.
Neuron cell bodies are shown by arrows. (H) GalNAcT/-Tg(neuronal) mice show surface deposits of AGAb in some dorsal root ganglion cells
24 h after passive immunization but show negligible presence of internal AGAb. (I) Hemisection of mid-cervical cord of GalNAcT/-Tg(neuronal)
mouse demonstrating the prominent distribution of AGAb in the ventral horn but not elsewhere. Scale bars: B–H = 20mm; I = 200 mm.
Non-parametric data are displayed as box and whisker plots.
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surrounding neuropil as would be expected following retro-
grade trafﬁcking (Fig. 1I). These data suggest that sensory
nerve uptake with retrograde trafﬁcking to the dorsal root
ganglia is not a major clearance pathway for AGAbs, com-
pared to the extensive contribution of NMJs, although we
do not exclude this possibility under other conditions and
antibody speciﬁcities.
We next evaluated the effects of neuromuscular synaptic
activity on antibody clearance rates in ex vivo wild-type
triangularis sterni neuromuscular preparations (Fig. 2).
Following initial labelling with anti-GD1b AGAb under
resting conditions at 4 C (under which state internalization
is limited), upon transfer to room temperature stimulated
NMJs showed considerably lower levels of AGAb on their
surface membrane than unstimulated NMJs (Fig. 2A). This
rapid internalization of surface AGAb was sufﬁcient to
reduce MAC deposition and damage to the NMJ
membrane in a complement-mediated injury paradigm
(Fig. 2B). In an acute exercise paradigm (forced treadmill
exercise), the additional motor activity served to increase,
rather than decrease the amount of antibody present at the
surface of the NMJs of the soleus (lower leg) muscle of
GalNAcT/-Tg(neuronal) mice. Intracellular AGAb was
also higher due to increased internalization by the active
nerve (Fig. 2C). We interpret the increase of AGAb at the
surface membrane as being due to increase ﬂow of blood to
the exercising muscle, thereby delivering more AGAb. In
this acute exercise model (conducted over 3 h) exercising
did not detectably change the overall levels of circulating
AGAb compared to controls (Fig. 2D). As a further control
experiment, BoNT/A was added to block vesicle release
(and therefore recycling) in triangularis sterni preparations
before stimulation. The addition of BoNT/A attenuated to
background levels the clearance of surface AGAb in re-
sponse to nerve stimulation (Fig. 2E). This reinforces the
notion that AGAb uptake is increased by synaptic activity.
Self-antigens including gangliosides are considered poor
immunogens due to the effects of tolerance in limiting auto-
immune responses (Nores et al., 2008). Previous active im-
munization studies aiming to generate AGAb responses
have used GalNAcT/ mice to bypass tolerance as wild-
type mice appear to respond poorly (Lunn et al., 2000;
Bowes et al., 2002). As the readout for active immunization
is assessment of serum AGAb levels, clearance by neuronal
endocytosis could confound interpretation of these
studies. To test this, wild-type, GalNAcT/ and
GalNAcT/-Tg(neuronal) mice were serially immunized
with GD1b and monitored for antibody production (Fig.
3A). Anti-GD1b titres were highest in GD1b-deﬁcient
GalNAcT/ mice, lowest in wild-type mice and intermedi-
ate in GalNAcT/-Tg(neuronal) mice by ELISA (Fig. 3B).
Serum from GalNAcT/ mice also showed the highest
ﬂuorescent signal to GD1b by glycoarray, both alone and
in complex with other lipids (Fig. 3C). These data indicate
that either tolerance or clearance is regulating AGAb levels
in wild-type mice. To examine this, we assessed GD1b anti-
gen-speciﬁc B cell frequency by ELISpot assays and found
comparable numbers of GD1b-speciﬁc B cells (combined
IgG and IgM) in wild-type and GalNAcT/ mice (Fig.
3D and E). These data indicate that wild-type and
GalNAcT/mice equally respond to ganglioside immuniza-
tion, but that the former prematurely deplete serum AGAb
by endocytosis. GalNAcT/-Tg(neuronal) mice most likely
respond to immunization similarly to other genotypes, but
clear AGAb solely though neuronal endocytosis. We were
unable to detect endocytosed IgG in the motor axon,
cell body or spinal cord of actively immunized
GalNAcT/-Tg(neuronal) mice, likely due to levels being
below the detection threshold.
Discussion
We have identiﬁed a major clearance pathway for AGAbs
that are harvested by peripheral nerve endocytosis (Fig. 4).
Estimating the surface area of the human NMJ presynaptic
membrane at 0.1 m2 (Supplementary material), this rep-
resents a sizable sink for depleting circulating IgG and
other factors that bind this endocytically active membrane.
The local and/or distant neurotoxic effects of internalized
and retrogradely transported AGAb are unknown, as are
the onward trafﬁcking and catabolic pathways, but could
mediate CNS manifestations of Guillain-Barre´ syndrome
variants. Inhibitory interneuron damage, as seen in tetanus
toxicity, could be implicated in the hyper-reﬂexia seen in
AGAb-associated AMAN (acute motor axonal neuropathy)
cases (Kuwabara et al., 1999; Yuki et al., 2012). Similarly,
injury to the reticular activating system adjacent to oculo-
motor nuclei in the brainstem from endocytosed AGAb
may underlie the coma seen in the Bickerstaff’s brainstem
encephalitis variant of Guillain-Barree´ syndrome
(Shahrizaila and Yuki, 2013). Antibodies against unidenti-
ﬁed synaptic membrane components have previously been
shown to translocate from spinal cord neurons following
retrograde trafﬁcking from the periphery (Wenthold et al.,
1984; Ritchie et al., 1986; Fabian, 1988). Most studies re-
porting ingress of autoantibodies into the CNS assume they
are delivered through the blood–brain barrier (Wootla et
al., 2015; Xu et al., 2015). However peripheral neuron
uptake merits further consideration. Equally, ganglioside
binding proteins, such as -synuclein and amyloid-b pep-
tides could be delivered from the systemic circulation to the
CNS through a NMJ uptake route (Hoshino et al., 2013;
Sacino et al., 2014).
Endocytic clearance of circulating antibody by self-anti-
gen confounds interpretation of studies dependent upon
measuring serum antibody levels. Not all AGAbs are
neurotoxic as exempliﬁed in this study by using the anti-
GM1 antibodies DG1 and DG2. During polyclonal AGAb
responses, non-tissue binding AGAbs that cannot be
cleared by endocytosis will predominate in the circulation
over tissue binding AGAbs, thereby misrepresenting the di-
versity of the AGAb repertoire. In neuropathy research,
harmless AGAbs will be the predominant circulating
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Figure 2 Uptake at the nerve terminal is activity dependent. (A) Wild-type triangularis sterni muscle (n = 3) was labelled with anti-
GD1b antibody, then washed and the intercostal nerves of one hemi-triangularis sterni per mouse was stimulated, while the other remained
unstimulated. Once analysed, tissue was permeabilized, reprobed with secondary antibody and reanalysed for antibody presence. Unstimulated
nerve terminals show a higher presence of membrane anti-GD1b antibody than stimulated nerve terminals. Stimulated nerve terminals still
showed presence of anti-GD1b antibody at distal nodes of Ranvier (white arrowhead). Following permeabilization and reprobing with secondary
antibody, anti-GD1b intensity in stimulated tissue was no different than unstimulated tissue (P5 0.0001 versus unstimulated, Mann-Whitney
test). (B) In ex vivo preparations, stimulation can protect the nerve terminal from complement-mediated injury. When normal human serum is
6 | BRAIN 2016: Page 6 of 9 M. E. Cunningham et al.







species, thereby confounding pathogenesis studies that rely
on demonstrating neurotoxic effect with human or animal
sera (Greenshields et al., 2009; Galban-Horcajo et al.,
2014). These data help to resolve longstanding enigmas
surrounding AGAb in the context of immune homeostasis
and disease, in addition to raising new clinical and basic
research questions.
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Figure 2 Continued
added to triangularis sterni muscles (n = 3), which were labelled with anti-GD1b antibody and subsequently stimulated, deposition of MAC over
motor nerve terminals is reduced when compared to unstimulated nerve terminals (P5 0.0001 versus unstimulated, Mann-Whitney test).
This is accompanied by retention of cytosolic CFP in the nerve terminal. White arrow head indicates expected position of CFP as indicated by
BTx. Fisher’s Exact Test indicated that stimulated triangularis sterni had more healthy NMJs than unstimulated as indicated by the presence of CFP
(displayed as mean % of total junctions analysed). P5 0.0001 versus unstimulated. (C) In an acute exercise paradigm, the intensity of anti-
GD1b antibody present at whole-mount soleus muscle motor nerve terminals is higher in exercised GalNAcT/-Tg(neuronal) mice compared
with unexercised mice (n = 3 per group) even after permeabilization and re-probing with secondary antibody. (D) In the same exercise paradigm,
no significant difference exists between the serum levels of anti-GD1b antibody in exercised and unexercised GalNAcT/-Tg(neuronal) mice. (E)
In a control experiment (n = 1 mouse for unstimulated, stimulated  BoNT/A, n = 2 mice for stimulated + BoNT/A, minimum 62 NMJs analysed
per group), BoNT/A inhibited the uptake of AGAb caused by stimulation. Scale bars = 20 mm. Non-parametric data are displayed as box and
whisker plots.
Figure 3 Serum levels of AGAb in actively immunized mice are attenuated by endocytic clearance. (A) Immunization protocol.
(B) Anti-GD1b specific ELISA show serum levels of anti-GD1b IgM and IgG were higher in the GalNAcT/ mice (n = 4) than the wild-type mice
(n = 6), with intermediate values for GalNAcT/-Tg(neuronal) mice (n = 6) (P5 0.05 versus wild-type, two-way ANOVA with Tukey’s multiple
comparison test). (C) Glycoarray analysis showing illustrative IgM and IgG responses at Day 22 to GD1b and other liposome components both
alone and in complex. Arrays are interpreted by reading along both axes to find the resulting combination of lipids, with a line of symmetry
marked by white crosses. Numbers represent lipids as follows: 0 = methanol (diagonally), 1 = GD1b, 2 = sphingomyelin, 3 = GM1, 4 = cholesterol,
5 = dicetylphosphate, 6 = GT1b. The GD1b columns are highlighted by a red box. (D) Illustrative ELISpot wells show similar spot numbers
between GalNAcT/ and wild-type mice. (E) Positive IgG + IgM spots per well for each genotype ( + SEM) from wild-type and GalNAcT/
mouse splenocytes show no significant difference between wild-type (n = 4) and GalNAcT/ mice (n = 4) (Student t-test).
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Figure 4 Schematic representation of anti-ganglioside antibody internalization. At the nerve terminal, pathogenic and non-patho-
genic anti-ganglioside antibodies (that can and cannot bind their ganglioside target when embedded in the plasma membrane, respectively) arrive
from the circulation (1). Vesicles containing ACh fuse with the membrane during neurotransmitter release and during activity-independent vesicle
recycling (2), pathogenic antibody species bind to gangliosides. During vesicle retrieval, gangliosides and their attached antibodies are internalized
(3). Antibodies may be directly recycled to the plasma membrane (4), or undergo retrograde axonal transport to the motor neuron cell body in
the spinal cord (5). Pathogenic anti-ganglioside antibody, which also binds at the node of Ranvier, cannot be significantly internalized, and therefore
activate complement, resulting in MAC deposition and nodal injury (6). Non-pathogenic antibodies are unbound and freely circulate in the
interstitial environment of the nerve terminal and are not detectably internalized (7). Retrogradely transported antibody residing in the soma of
motor neurons may be degraded in lysosomes (8), or recycled to the neuron surface (9) and secreted, free to bind to adjacent neurons and
potentially mediate pathogenic effects (10). Elsewhere in the body, circulating pathogenic antibodies may bind to their target ganglioside in the
membrane of non-neuronal cells. Once bound, antibodies may be endocytosed thus cleared from the circulation (11), again leaving only non-
pathogenic antibodies to circulate in the serum. These will be the preferential antibody species detected by solid-phase assays such as ELISA.
Exocytic pathways are shown by green arrows while endocytic pathways are shown by red arrows.
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Supplementary material is available at Brain online.
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